SCHEMBL5134693

SCHEMBL5134693

CCCCN(Cc1ccc(O)c(C)c1)Cc1c(-c2ccc(F)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.45
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
CRHR1 P34998 3/20 0.38
BCHE P06276 4/20 0.36
TSHR P16473 2/20 0.35
HDAC1 Q13547 1/20 0.35
PDK1 Q15118 1/20 0.34
ATP4A P20648 1/20 0.34
ATP4B P51164 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP3A4 P08684 2/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
MMP1 P03956 1/20 0.34
MMP13 P45452 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649712 0.95 C5AR1 (0.49) C5AR1ESR1ESR2CRHR1BCHE
SCHEMBL5074276 0.92 C5AR1 (0.47) C5AR1ESR1ESR2CRHR1BCHE
SCHEMBL5135148 0.91 C5AR1 (0.45) C5AR1ESR1ESR2CRHR1BCHE
SCHEMBL5137380 0.91 C5AR1 (0.41) C5AR1CRHR1BCHETSHRHDAC1
SCHEMBL5135588 0.91 C5AR1 (0.45) C5AR1ESR1ESR2CRHR1BCHE
SCHEMBL5070033 0.90 C5AR1 (0.41) C5AR1CRHR1KDM4E
SCHEMBL5135954 0.90 C5AR1 (0.44) C5AR1ESR1ESR2BCHETSHR
SCHEMBL5135240 0.89 C5AR1 (0.42) C5AR1CRHR1BCHETSHRPDK1
SCHEMBL650018 0.89 C5AR1 (0.46) C5AR1ESR1ESR2CRHR1BCHE
SCHEMBL5136707 0.89 MAPT (0.42) C5AR1CRHR1ATP4AATP4BMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed